1. Dr. Reddy's Laboratories
stock logo

50% Buy

Dr. Reddy's Laboratories Share Price

DRREDDY

₹6,078.40+₹23.45 (0.39%) TodayLast updated on 25 Jun, 2024 | 03:59 PM IST
₹6,016.05₹6,095.20
L
Show Current Price
H
  • News

  • Company overview

  • Fundamentals

  • Events

  • More

Company overview

Financial performance

arrow

Market cap

Market Cap Switch₹1,01,341 Crs

Open

₹6,090.00

Close

₹6,054.95

Circuit range

₹6,660.40 - ₹5,449.45

Day range

₹6,016.05 - ₹6,095.20

Year range

₹4,952.00 - ₹6,505.90

Volume

3,95,498

Avg. traded

₹6,052.18

Revenue (12m)

₹28,011 Crs

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is an Indian pharmaceutical company that was founded in 1984 by Kallam Anji Reddy. Headquartered in Hyderabad, the company produces over 190 medications and over 60 active pharmaceutical ingredients (APIs).

The market capitalisation of Dr. Reddy's Laboratories Limited was ₹97,400 crore as of January 4, 2024. The share price of Dr. Reddy's has gained over 10% in the last three years

Business Operations

Dr. Reddy's Laboratories has been an active player in the pharmaceutical sector for more than 20 years. Its expertise lies in Active Pharmaceutical Ingredients (API), boasting a diverse portfolio. They specialise in manufacturing generic medicines with operations in India, Russia, US and Germany.

The company also engages in proprietary products, biologics business and unique formulations conducted primarily in the US. It has introduced Grafeel (Filgrastim), a drug used to fight infections after chemotherapy, and Reditux (Rituximab), an ant-cancer drug.

Dr. Reddy's produces a diverse range of intricate APIs and holds over 1,150 drug master files covering key therapy areas like oncology, cardiovascular, central nervous system and anti-diabetes. With 22 manufacturing facilities worldwide, the company ensures top-quality output and timely supply to markets. Its expertise in Active Pharmaceutical Ingredients (API) spans 8 manufacturing units globally.

The company’s largest manufacturing facility is located in Bachupally, Hyderabad. As of FY22, it has filed 1,071 patents and published over 1,000 papers.

Central to its R&D excellence is the Integrated Product Development Organisation (IPDO) situated in Hyderabad. This extensive campus hosts multiple laboratories, including the latest addition, a nutraceutical R&D centre. These cutting-edge labs are powered by a diverse team of scientists recruited from leading institutions worldwide.

The dedicated efforts of Dr. Reddy's in product development support a portfolio exceeding 1,000 products. The pharma giant has an R&D team comprising over 150 doctorates.

The company is focused on research and has a strong team of over 3,000 scientists in 8 R&D facilities. As of March 31, 2023, Dr. Reddy's is powered by a workforce of 25,498 permanent employees and workers in 74 countries.

The business of Dr. Reddy's Laboratories in branded generics thrives not only in India but also in emerging markets globally. Its branded products reach over 30 countries, spanning Asia, Africa, Australia, New Zealand, Russia, Romania, China and Latin America.

The company's growth rate has doubled in the past four years. It has reached a prominent position in crucial therapy areas like oncology, gastroenterology, allergy, diabetes and pain management. Within its Indian operations, it structures its business according to therapies, managing over 300 brands. Its extensive reach to healthcare professionals is facilitated by a field force comprising approximately 7,500 members.

Financial Highlights

The revenue from operations for FY23 stood at ₹24,669.7 crore, up 14.5% from ₹21,545.2 crore in FY22. The company recorded a Profit after Tax (PAT) of ₹4,507.3 crore in FY23 against ₹2,182.5 crore in FY22. In FY23, the earnings before interest, tax, depreciation and amortisation (EBITDA) increased to ₹7,308.1 crore from the previous year's ₹5,140 crore. Dr. Reddy's earnings per share (EPS) stood at ₹271.47 in FY23 compared to ₹131.57 in the previous financial year.

Dr. Reddy's Laboratories Key indicators

arrow

52 week high

₹6,505.90

52 week low

₹4,952.00

P/E ratio

18.19

P/B ratio

3.59

ROE

13.57%

ROCE

18.91%

Dividend yield

0.67%

Debt/Equity ratio

EPS

156.83

Learn more

Investment checklist: (5/6)

arrow
check status

Equity returns

check status

Dividend returns

check status

Safety factor

check status

Growth factor

check status

Debt vs Equity

check status

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst ratings:

Buy

arrow

Buy

50%

Hold

24%

Sell

26%

This analysis is based on the reviews of 34 experts in the last 7 days

Brands by Dr. Reddy's Laboratories

arrow
brand logo

DrReddy

brand logo

Econorm

brand logo

Nise

brand logo

Omez

brand logo

Razo

brand logo

Stamlo

Fundamentals

Financial ratios

arrow
  • Profitability

  • Operational

  • Valuation

Operating profit margin

28.33%

Net profit margin

15.4%

ROE

13.57%

ROA

10.48%

ROCE

18.91%

Learn more

Dr. Reddy's Laboratories Shareholder returns

arrow

1 day

+0.72%

1 week

-0.50%

1 month

+3.23%

3 months

-2.39%

1 year

+21.25%

3 years

+14.73%

5 years

+140.91%

Dr. Reddy's Laboratories Share Price history

arrow
DayOpenCloseDay’s change
Mon, Jun 24 2024
₹5,998.00
₹6,054.95
+0.72%
Fri, Jun 21 2024
₹5,971.00
₹6,011.45
+0.68%
Thu, Jun 20 2024
₹5,925.00
₹5,970.80
+0.25%
Wed, Jun 19 2024
₹5,991.95
₹5,956.20
-0.59%
Tue, Jun 18 2024
₹6,048.00
₹5,991.25
-1.54%
Fri, Jun 14 2024
₹6,096.00
₹6,085.25
-0.17%
Thu, Jun 13 2024
₹6,119.90
₹6,095.85
+0.59%
Wed, Jun 12 2024
₹6,060.00
₹6,060.05
+0.34%

Shareholding info

arrow

Promoters (26.65%)

Mutual Funds (7.96%)

Retail and other (25.9%)

Foreign institutions-FII (29.13%)

Other domestic institutions (10.35%)

Foreign institutions-FII

Learn more

Events

Corporate actions

arrow
  • Dividend • ₹40/share

    Ex date 11 Jul 2023

    expand tab
  • Dividend • ₹30/share

    Ex date 11 Jul 2022

    expand tab
  • Dividend • ₹40/share

    Ex date

    expand tab

Learn more

Frequently asked questions